Blocking autoantibody secretion in CVID patients with ITP by IL-2 restored Tregs
通过 IL-2 阻断 CVID 合并 ITP 患者的自身抗体分泌可恢复 Tregs
基本信息
- 批准号:8805484
- 负责人:
- 金额:$ 8.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-12-15 至 2015-08-01
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvisory CommitteesAntibodiesAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmune ProcessAutoimmunityAutologousAwardB Cell ProliferationB-LymphocytesBLR1 geneCell Culture TechniquesCell physiologyCell surfaceCellsCharacteristicsChronicClinicalClinical DataClinical ImmunologyClinical TrialsCoculture TechniquesDataDefectDeficiency DiseasesDevelopmentDiseaseDoctor of PhilosophyDoseEnvironmentFunctional disorderGene ExpressionGene Expression ProfilingGene MutationGenesGeneticGoalsHelper-Inducer T-LymphocyteHomeostasisHumanHuman GeneticsImmuneImmunobiologyImmunoglobulin Class SwitchingImmunoglobulin GImmunoglobulin IsotypesIn VitroInterleukin-10Interleukin-2Interleukin-4InterleukinsInternationalInvestigationK-Series Research Career ProgramsMaintenanceMeasuresMediatingMedicalMemory B-LymphocyteMentorsMolecularMorbidity - disease rateMusNorth AmericaNuclearOutcomePAX5 genePRDM1 genePatientsPediatricsPlasma CellsPlasmablastPopulationPositioning AttributePrevalenceProductionProphylactic treatmentQualifyingRegulatory T-LymphocyteReplacement TherapyResearchResearch PersonnelResourcesRoleSamplingScientistSerumShapesStructureSurfaceT-LymphocyteThrombocytopeniaTrainingTranscriptTranslatingTranslational ResearchUnited States National Institutes of HealthUniversitiesWorkautoreactive B cellcareerchemokine receptorcohortcommon treatmentconditioningcytokinecytopeniadesignexperienceimprovedinterestkillingsmortalitypatient oriented researchperipheral bloodplasma cell differentiationpre-clinicalprogramspublic health relevanceresearch studyresponsetherapy development
项目摘要
DESCRIPTION (provided by applicant): The overarching goal of this five-year proposal is development of the candidate into an independent investigator leading a robust translational research program in the field of primary immune deficiencies. The candidate is optimally positioned, through his background of structured training in clinical immunology and extensive research experience in human immunobiology, to fully realize the benefits of a NIH mentored career development award.
The proposal promotes a line of investigation leading directly to the introduction of new therapies specifically tailored for common variable immune deficient patients with autoantibody-mediated autoimmune diseases. The candidate has assembled an outstanding team of mentors uniquely qualified to assist in accomplishing his long-term research goals. The team includes Eric Meffre, PhD, a pioneer in the field of B cell tolerance, Charlotte Cunningham-Rundles, MD PhD, an international expert in common variable immune deficiency and Richard Lifton, MD PhD, a leader in human genetics with specific strength in high-throughput approaches. A less formal advisory committee of highly-regarded medical scientists, Drs. Pober, Hafler and Craft have each advised the candidate on aspects of his proposal and will provide additional ongoing scientific/career advice. The candidate has also proposed a program of didactic coursework and hands-on experiences designed to promote investigator independence at the conclusion of the award period.
Research will focus on regulatory T cell (Treg) suppression of autoantibody secretion in humans. Preliminary data suggests that Tregs from healthy donors do not interact with B cells directly but control them through a T effector intermediary. In CVID patients with autoimmune cytopenias there is loss of this control due to Treg dysfunction and the abundance of circulating T effector population, resembling follicular T cells (Tfh), that drives autoantibody secretion. Specific aims of the proposal include: 1) investigating the molecular mechanism employed by Tregs to influence B cells in vitro 2) determining how Tfh-like cells from CVID patients with ITP differ from phenotypicall similar populations in primary ITP patients and healthy donors at the gene expression level and also functionally in terms of how they shape the reactivities of secreted antibodies, and 3) demonstrating the effect of IL-2 restored CVID Tregs on Tfh-like-driven autoantibody secretion. Together the aims of the proposal have been designed to generate pre-clinical data to support a clinical trial of low-dose IL-2 in CVID patients with autoimmune cytopenias.
In addition to their own merits, the candidate and his proposal are further enriched by the ideal academic environment and extensive resources provided by Yale University's Departments of Immunobiology, Genetics and Pediatrics. The candidate has access to rare patient samples through his own Yale CVID cohort and the nearby CVID cohort of Dr. Cunningham-Rundles, the largest in North America, if not the world. In brief, this application proposes a plan of research that is relevant, important and achievable. It is a plan designed to culminate in the candidate establishing an independent patient- oriented research program in an academic setting.
描述(由申请人提供):这个五年计划的总体目标是将候选人发展成为一名独立的研究者,领导原发性免疫缺陷领域强有力的转化研究项目。通过他在临床免疫学方面的结构化培训背景和在人类免疫生物学方面的广泛研究经验,该候选人处于最佳位置,可以充分实现NIH指导的职业发展奖的好处。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NEIL David ROMBERG其他文献
NEIL David ROMBERG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NEIL David ROMBERG', 18)}}的其他基金
Promoter interactome-aided mapping of unexplored CVID genetic landscapes
未探索的 CVID 遗传景观的启动子相互作用组辅助绘图
- 批准号:
10207385 - 财政年份:2019
- 资助金额:
$ 8.33万 - 项目类别:
Promoter interactome-aided mapping of unexplored CVID genetic landscapes
未探索的 CVID 遗传景观的启动子相互作用组辅助绘图
- 批准号:
10443566 - 财政年份:2019
- 资助金额:
$ 8.33万 - 项目类别:
Promoter interactome-aided mapping of unexplored CVID genetic landscapes
未探索的 CVID 遗传景观的启动子相互作用组辅助绘图
- 批准号:
9978706 - 财政年份:2019
- 资助金额:
$ 8.33万 - 项目类别:
Promoter interactome-aided mapping of unexplored CVID genetic landscapes
未探索的 CVID 遗传景观的启动子相互作用组辅助绘图
- 批准号:
10640143 - 财政年份:2019
- 资助金额:
$ 8.33万 - 项目类别:
BLOCKING AUTOANTIBODY SECRETION IN CVID PATIENTS WITH ITP BY IL-2 RESTORED TREGS
通过 IL-2 恢复的 Tregs 阻断 CVID 患者的自身抗体分泌
- 批准号:
8985654 - 财政年份:2014
- 资助金额:
$ 8.33万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 8.33万 - 项目类别:
Standard Grant














{{item.name}}会员




